Safety Profile of the Adjuvanted Recombinant Zoster Vaccine: Pooled Analysis of Two Large Randomised Phase 3 Trials
The ZOE-50 and ZOE-70 phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. This article presents a comprehensive overview of the safety data from these studies. Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses…